Jump to content

Oxalobacter formigenes

From Wikipedia, the free encyclopedia

Oxalobacter formigenes
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Pseudomonadota
Class: Betaproteobacteria
Order: Burkholderiales
Family: Oxalobacteraceae
Genus: Oxalobacter
Species:
O. formigenes
Binomial name
Oxalobacter formigenes
Allison et al, 1985[1]
Type strain
Oxalobacter formigenes OxBT

Oxalobacter formigenes is a Gram negative oxalate-degrading anaerobic bacterium that was first isolated from the gastrointestinal tract of a sheep in 1985.[1] To date, the bacterium has been found to colonize the large intestines of numerous vertebrates, including humans, and has even been isolated from freshwater sediment.[2] It processes oxalate by decarboxylation into formate (oxalyl-CoA decarboxylase), producing energy for itself in the process.[3]

The broad-spectrum quinolone antibiotics kill O. formigenes.[citation needed] If a person's gastrointestinal (GI) tract lacks this bacterium, and therefore lacks the primary source of the oxalyl-CoA decarboxylase enzyme, then the GI tract cannot degrade dietary oxalates; after some vitamin B6-modulated partial metabolic degradation in the body, the oxalates are excreted in the kidney, where they precipitates to form calcium oxalate kidney stones.[4][5][6][7] Oxalobacter formigenes can protect against kidney stones by degrading oxalate.[7]

The role and presence of O. formigenes in the human gut is an area of active research.

Genome

[edit]
Genomic information
Genome size2.41-2.47 Mb[8][9][10]

The genome of O. formigenes has been sequenced by at least three different researchers. It has a G+C content of 49.6%.[9][11]

Taxonomy

[edit]

Based on fatty acid profile, 16S ribosomal RNA sequencing, and DNA probes specific to the oxc (oxalyl-CoA decarboxylase) gene and frc (formyl-CoA transferase), O. formigenes has been divided into two groups.[1][12][13][14] Group 1 has less diversity and better growth compared to group 2. To date, most research has focused on group 1 strains due to their ease of growth.

Interestingly, analysis with the DNA probes showed that group 2 may be further divided into two subgroups.[13] Whole genome sequencing has revealed that the original O. formigenes taxon can be divided into three additional species: Oxalobacter aliiformigenes, Oxalobacter paeniformigenes, and Oxalobacter paraformigenes.[11]

Metabolism

[edit]

O. formigenes uses oxalate as its primary carbon source.[1] Oxalate is absorbed through an oxalate:formate antiporter (OxlT) in a 1:1 proportion.[15] Imported oxalate is then converted to oxalyl-CoA via formyl-CoA transferase (frc). Oxalyl-CoA is decarboxylated using and H+ via oxalyl-CoA decarboxylase (oxc), releasing CO2, and generating formyl-CoA, which is used for the frc reaction. In total, approximately 1 mol of formate and CO2 are produced per mol of oxalate consumed.[16] 3H+ are imported via an ATPase to provide H+ for the decarboxylation reaction.[17]

Cell biomass generation

[edit]

Biomass in O. formigenes is primarily generated by oxalate consumption through the metabolism of oxalyl-CoA in the glycerate pathway.[18][19] Acetate and carbonate are also used for cell biomass, but to a lesser extent than oxalate.[18]

Growth in culture

[edit]

O. formigenes was isolated in oxalate containing anerobic media.[1] Currently, O. formigenes is grown in anaerobic Hungate tubes using a CO2-bicarbonate buffered oxalate media.[2] Optimal growth is achieved at a pH between 6 and 7. Oxalate is used at 20 mM for freezer recovery and general maintenance but concentrations can be increased to 100 mM for increased cell density. While oxalate is the main carbon source, small amounts of acetate and yeast extract are supportive of growth.[2][16] O. formigenes can reach stationary phase in approximately 24 – 48 hours but is sometimes delayed to 72 hours.

Enriched anaerobic complex media (e.g. Brain heart infusion) fail to support the growth of O. formigenes unless supplemented with oxalate. Therefore, these media can be used to assess the purity of O. formigenes cultures.

Antibiotic resistance and susceptibility

[edit]

Given the fastidious nature of O. formigenes, traditional methods for antibiotic susceptibility testing are not sufficient. Instead, bacteria are cultured in the presence of antibiotics and screened for viability using opaque anaerobic oxalate agar.[2][20][21] This method demonstrated that O. formigenes is resistant to nalidixic acid, ampicillin, amoxicillin, streptomycin, and vancomycin.[20][21] O. formigenes was also found to be susceptible to ciprofloxacin, clarithromycin, clindamycin, doxycycline, gentamicin, levofloxacin, metronidazole, and tetracycline.[20][21]

Prevalence in the mammalian gut

[edit]

O. formigenes is found in the mammalian gastrointestinal tract and often isolated from feces. In addition to culture-based methods, O. formigenes is presence is detected using molecular methods such as qPCR and next generation sequencing.

Humans

[edit]

Humans are not typically born with O. formigenes and only become colonized when they begin crawling around in their environment.[22] In adulthood, the frequency of O. formigenes in the gut microbiota varies across different populations. In North India, O. formigenes is prevalent in approximately 65% of the population.[23] In South Korea and Japan, O. formigenes is present in about 75% of individuals.[24][25] In the United States of America, O. formigenes is only detected in about 30% of the human population.[26][27] Populations who do not practice modern medicine or life in a Western lifestyle typically have an increased prevalence of O. formigenes, which could imply that these practices affect O. formigenes colonization.[28][29]

Ruminants

[edit]

The idea that ruminants are colonized by oxalate-degrading bacteria came from the observation that sheep grazing on oxalate-rich plants (e.g. Halogeton glomeratus) consumed large quantities of this plant and died of renal intoxication from oxalate.[2] However, by slowly acclimatizing sheep to high-oxalate intake, they would survive the consumption of large quantities of oxalate-rich plants.[30] This led to the proposal that resident oxalate-degrading bacteria were enriched by the gradual introduction to a oxalate-rich diet, which protected the sheep from oxalate-induced renal damage.[31][32] In 1980, the first oxalate-degrading bacteria were isolated from the rumen of sheep, and it was later named Oxalobacter formigenes.[1][16]

Clinical significance

[edit]

O. formigenes has been investigated for its role in mitigating calcium oxalate kidney stone disease and primary hyperoxaluria because it metabolizes oxalate as its primary carbon source.

Oxalate degradation in kidney stone disease

[edit]

In vitro experiments find that O. formigenes is a specialist oxalate consuming bacteria that can degrade oxalate more efficiently than other generalist oxalate consuming bacteria.[33] Initial research pointed to the loss of oxalate-degrading bacteria, such as O. formigenes, following antibiotic usage as primary contributor to calcium oxalate kidney stone disease.[34][35] Colonization with O. formigenes has been observed to results in a decrease in urinary oxalate[35][4] and reduced frequency of kidney stones[4][7][36]

Recent work using next-generation sequencing has found that O. formigenes colonizes both calcium oxalate kidney stone formers and non-stone forming controls.[37][38] This observation has led to the notion that O. formigenes alone may not be responsible for regulating oxalate degradation in the gut microbiota, but instead it may be part of a network of co-occurring bacterial taxa that modulate oxalate degradation together.[39][40][41]

Secretagogues to promote intestinal oxalate dumping in kidney stone disease

[edit]

It has been proposed that O. formigenes produces secretagogues that can stimulate oxalate transport in epithelial cells. While epithelial oxalate secretion has been shown in human cell lines and rodent models,[42][43] it has not been confirmed in humans. Candidate bioactive molecules have been identified and tested in animal models.[42][44]

O. formigenes as a therapeutic for primary hyperoxaluria

[edit]

In a small study, oral supplementation with O. formigenes HC-1 along with a loading dose of oxalate resulted in reduced oxalate excretion during the 6 h immediately following ingestion.[20] Multiple clinical trials in populations with primary hyperoxaluria have demonstrated that O. formigenes supplementation is safe and well tolerated but data are mixed on the capability of O. formigenes to establish in hosts and reduce urinary and plasma concentrations of oxalate.[45][46][47][48][49]


References

[edit]
  1. ^ a b c d e f Allison MJ, Dawson KA, Mayberry WR, Foss JG (February 1985). "Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract". Archives of Microbiology. 141 (1): 1–7. Bibcode:1985ArMic.141....1A. doi:10.1007/BF00446731. PMID 3994481. S2CID 10709172.
  2. ^ a b c d e Daniel SL, Moradi L, Paiste H, Wood KD, Assimos DG, Holmes RP, et al. (August 2021). Pettinari JM (ed.). "Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist". Applied and Environmental Microbiology. 87 (18): e0054421. Bibcode:2021ApEnM..87E.544D. doi:10.1128/AEM.00544-21. PMC 8388816. PMID 34190610.
  3. ^ Unden G (2013). "Energy Transduction in Anaerobic Bacteria". Encyclopedia of Biological Chemistry. pp. 204–209. doi:10.1016/B978-0-12-378630-2.00282-6. ISBN 978-0-12-378631-9.
  4. ^ a b c Troxel SA, Sidhu H, Kaul P, Low RK (April 2003). "Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate". Journal of Endourology. 17 (3): 173–176. doi:10.1089/089277903321618743. PMID 12803990.
  5. ^ Tunuguntla HS (2001). "Can the recurrence of oxalate stones be prevented? Role of Oxalobacter formigenes in stone recurrence". Journal of Urology. 165: S246.
  6. ^ Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al. (August 2014). "Medical management of kidney stones: AUA guideline". The Journal of Urology. 192 (2): 316–324. doi:10.1016/j.juro.2014.05.006. PMID 24857648. S2CID 206623478.
  7. ^ a b c Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A (June 2013). "The role of Oxalobacter formigenes colonization in calcium oxalate stone disease". Kidney International. 83 (6): 1144–1149. doi:10.1038/ki.2013.104. PMID 23536130.
  8. ^ Sun NY, Gao Y, Yu HJ (October 2019). Stewart FJ (ed.). "Genome Sequence of Oxalobacter formigenes Strain SSYG-15". Microbiology Resource Announcements. 8 (42): e01059–19. doi:10.1128/MRA.01059-19. PMC 6797538. PMID 31624173.
  9. ^ a b Hatch M, Allison MJ, Yu F, Farmerie W (July 2017). "Genome Sequence of Oxalobacter formigenes Strain OXCC13". Genome Announcements. 5 (28): e00534–17. doi:10.1128/genomeA.00534-17. PMC 5511905. PMID 28705966.
  10. ^ Hatch M, Allison MJ, Yu F, Farmerie W (July 2017). "Genome Sequence of Oxalobacter formigenes Strain HC-1". Genome Announcements. 5 (27): e00533–17. doi:10.1128/genomeA.00533-17. PMC 5502849. PMID 28684568.
  11. ^ a b Chmiel JA, Carr C, Stuivenberg GA, Venema R, Chanyi RM, Al KF, et al. (2022-12-21). "New perspectives on an old grouping: The genomic and phenotypic variability of Oxalobacter formigenes and the implications for calcium oxalate stone prevention". Frontiers in Microbiology. 13: 1011102. doi:10.3389/fmicb.2022.1011102. PMC 9812493. PMID 36620050.
  12. ^ Jensen NS, Allison MJ (1994). Studies on the diversity among anaerobic oxalate-degrading bacteria now in the species Oxalobacter formigenes, abstr. I-12. 94th General Meeting of the American Society for Microbiology 1994. Washington, D.C., USA: American Society for Microbiology. p. 255.
  13. ^ a b Sidhu H, Allison M, Peck AB (February 1997). "Identification and classification of Oxalobacter formigenes strains by using oligonucleotide probes and primers". Journal of Clinical Microbiology. 35 (2): 350–353. doi:10.1128/jcm.35.2.350-353.1997. PMC 229578. PMID 9003594.
  14. ^ Garrity GM, Bell JA, Lilburn T (2005). "Class II. Betaproteobacteria class. nov.". In Brenner DJ, Krieg NR, Staley JT (eds.). Bergey's Manual® of Systematic Bacteriology. Boston, MA: Springer US. pp. 575–922. doi:10.1007/978-0-387-29298-4_2. ISBN 978-0-387-24145-6. Retrieved 2022-11-10.
  15. ^ Anantharam, V; Allison, M J; Maloney, P C (1989). "Oxalate:formate exchange". Journal of Biological Chemistry. 264 (13): 7244–7250. doi:10.1016/S0021-9258(18)83227-6.
  16. ^ a b c Dawson KA, Allison MJ, Hartman PA (October 1980). "Isolation and some characteristics of anaerobic oxalate-degrading bacteria from the rumen". Applied and Environmental Microbiology. 40 (4): 833–839. Bibcode:1980ApEnM..40..833D. doi:10.1128/aem.40.4.833-839.1980. PMC 291667. PMID 7425628.
  17. ^ Kuhner, C H; Hartman, P A; Allison, M J (1996). "Generation of a proton motive force by the anaerobic oxalate-degrading bacterium Oxalobacter formigenes". Applied and Environmental Microbiology. 62 (7): 2494–2500. Bibcode:1996ApEnM..62.2494K. doi:10.1128/aem.62.7.2494-2500.1996. ISSN 0099-2240. PMC 168031. PMID 8779588.
  18. ^ a b Cornick, N. A.; Allison, M. J. (1996). "Assimilation of oxalate, acetate, and CO 2 by Oxalobacter formigenes". Canadian Journal of Microbiology. 42 (11): 1081–1086. doi:10.1139/m96-138. ISSN 0008-4166. PMID 8941983.
  19. ^ Cornick, N A; Allison, M J (1996). "Anabolic Incorporation of Oxalate by Oxalobacter formigenes". Applied and Environmental Microbiology. 62 (8): 3011–3013. Bibcode:1996ApEnM..62.3011C. doi:10.1128/aem.62.8.3011-3013.1996. ISSN 0099-2240. PMC 1388924. PMID 16535386.
  20. ^ a b c d Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS (August 2002). "Oxalobacter formigenes and its potential role in human health". Applied and Environmental Microbiology. 68 (8): 3841–3847. Bibcode:2002ApEnM..68.3841D. doi:10.1128/AEM.68.8.3841-3847.2002. PMC 124017. PMID 12147479.
  21. ^ a b c Lange JN, Wood KD, Wong H, Otto R, Mufarrij PW, Knight J, et al. (June 2012). "Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics". Urology. 79 (6): 1286–1289. doi:10.1016/j.urology.2011.11.017. PMC 3569510. PMID 22656407.
  22. ^ Sidhu H, Enatska L, Ogden S, Williams WN, Allison MJ, Peck AB (June 1997). "Evaluating Children in the Ukraine for Colonization With the Intestinal Bacterium Oxalobacter formigenes, Using a Polymerase Chain Reaction-based Detection System". Molecular Diagnosis. 2 (2): 89–97. doi:10.1016/S1084-8592(97)80015-X. PMID 10462596.
  23. ^ Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD (March 2002). "Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India". European Urology. 41 (3): 318–322. doi:10.1016/S0302-2838(02)00040-4. PMID 12180235.
  24. ^ Kwak C, Jeong BC, Kim HK, Kim EC, Chox MS, Kim HH (May 2003). "Molecular epidemiology of fecal Oxalobacter formigenes in healthy adults living in Seoul, Korea". Journal of Endourology. 17 (4): 239–243. doi:10.1089/089277903765444384. PMID 12816588.
  25. ^ Kodama T, Mikami K, Akakura K, Takei K, Naya Y, Ueda T, Ito H (July 2003). "[Detection of Oxalobacter formigenes in human feces and study of related genes in a new oxalate-degrading bacterium]". Hinyokika Kiyo. Acta Urologica Japonica. 49 (7): 371–376. PMID 12968475.
  26. ^ Barnett C, Nazzal L, Goldfarb DS, Blaser MJ (February 2016). "The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults". The Journal of Urology. 195 (2): 499–506. doi:10.1016/j.juro.2015.08.070. PMC 4747808. PMID 26292041.
  27. ^ Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW (April 2011). "Factors related to colonization with Oxalobacter formigenes in U.S. adults". Journal of Endourology. 25 (4): 673–679. doi:10.1089/end.2010.0462. PMC 3071521. PMID 21381959.
  28. ^ PeBenito A, Nazzal L, Wang C, Li H, Jay M, Noya-Alarcon O, et al. (January 2019). "Comparative prevalence of Oxalobacter formigenes in three human populations". Scientific Reports. 9 (1): 574. Bibcode:2019NatSR...9..574P. doi:10.1038/s41598-018-36670-z. PMC 6346043. PMID 30679485.
  29. ^ Clemente JC, Pehrsson EC, Blaser MJ, Sandhu K, Gao Z, Wang B, et al. (April 2015). "The microbiome of uncontacted Amerindians". Science Advances. 1 (3). Bibcode:2015SciA....1E0183C. doi:10.1126/sciadv.1500183. PMC 4517851. PMID 26229982.
  30. ^ James LF, Cronin EH (November 1974). "Management practices to minimize death losses of sheep grazing Halogeton-infested range". Journal of Range Management. 27 (6): 424–426. doi:10.2307/3896714. hdl:10150/647155. JSTOR 3896714.
  31. ^ Allison MJ, Littledike ET, James LF (November 1977). "Changes in ruminal oxalate degradation rates associated with adaptation to oxalate ingestion". Journal of Animal Science. 45 (5): 1173–1179. doi:10.2527/jas1977.4551173x. PMID 599103.
  32. ^ Daniel SL, Cook HM, Hartman PA, Allison MJ (August 1989). "Enumeration of anaerobic oxalate-degrading bacteria in the ruminal contents of sheep". FEMS Microbiology Letters. 62 (5): 329–334. doi:10.1111/j.1574-6968.1989.tb03387.x.
  33. ^ Federici F, Vitali B, Gotti R, Pasca MR, Gobbi S, Peck AB, Brigidi P (September 2004). "Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis". Applied and Environmental Microbiology. 70 (9): 5066–5073. Bibcode:2004ApEnM..70.5066F. doi:10.1128/AEM.70.9.5066-5073.2004. PMC 520889. PMID 15345383.
  34. ^ Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, Peck AB (September 1998). "Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria". Lancet. 352 (9133): 1026–1029. doi:10.1016/S0140-6736(98)03038-4. PMID 9759746. S2CID 25936201.
  35. ^ a b Mittal RD, Kumar R, Bid HK, Mittal B (January 2005). "Effect of antibiotics on Oxalobacter formigenes colonization of human gastrointestinal tract". Journal of Endourology. 19 (1): 102–106. doi:10.1089/end.2005.19.102. PMID 15735393.
  36. ^ Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, Cave DR (June 2008). "Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones". Journal of the American Society of Nephrology. 19 (6): 1197–1203. doi:10.1681/ASN.2007101058. PMC 2396938. PMID 18322162.
  37. ^ Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, et al. (November 2018). "16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones". Urolithiasis. 46 (6): 503–514. doi:10.1007/s00240-018-1037-y. PMID 29353409. S2CID 11340007.
  38. ^ Ticinesi A, Milani C, Guerra A, Allegri F, Lauretani F, Nouvenne A, et al. (December 2018). "Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers". Gut. 67 (12): 2097–2106. doi:10.1136/gutjnl-2017-315734. PMID 29705728. S2CID 14055215.
  39. ^ Ticinesi A, Nouvenne A, Meschi T (July 2019). "Gut microbiome and kidney stone disease: not just an Oxalobacter story". Kidney International. 96 (1): 25–27. doi:10.1016/j.kint.2019.03.020. PMID 31229040. S2CID 195327195.
  40. ^ Miller AW, Choy D, Penniston KL, Lange D (July 2019). "Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis". Kidney International. 96 (1): 180–188. doi:10.1016/j.kint.2019.02.012. PMC 6826259. PMID 31130222.
  41. ^ Liu M, Koh H, Kurtz ZD, Battaglia T, PeBenito A, Li H, et al. (August 2017). "Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project". Microbiome. 5 (1): 108. doi:10.1186/s40168-017-0316-0. PMC 5571629. PMID 28841836.
  42. ^ a b Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, et al. (March 2017). "Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells". Journal of the American Society of Nephrology. 28 (3): 876–887. doi:10.1681/ASN.2016020132. PMC 5328155. PMID 27738124.
  43. ^ Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW (February 2006). "Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion". Kidney International. 69 (4): 691–698. doi:10.1038/sj.ki.5000162. PMID 16518326.
  44. ^ Arvans D, Chang C, Alshaikh A, Tesar C, Babnigg G, Wolfgeher D, et al. (July 2023). "Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells". American Journal of Physiology. Cell Physiology. 325 (1): C344–C361. doi:10.1152/ajpcell.00466.2021. PMC 10393326. PMID 37125773.
  45. ^ Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, et al. (November 2011). "Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria". Nephrology, Dialysis, Transplantation. 26 (11): 3609–3615. doi:10.1093/ndt/gfr107. PMID 21460356.
  46. ^ Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, et al. (May 2017). "A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria". Pediatric Nephrology. 32 (5): 781–790. doi:10.1007/s00467-016-3553-8. PMID 27924398. S2CID 52271121.
  47. ^ Milliner D, Hoppe B, Groothoff J (August 2018). "A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria". Urolithiasis. 46 (4): 313–323. doi:10.1007/s00240-017-0998-6. PMC 6061479. PMID 28718073.
  48. ^ Hoppe, Bernd; Pellikka, Patricia A; Dehmel, Bastian; Banos, Ana; Lindner, Elisabeth; Herberg, Ulrike (2021-07-23). "Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study". Nephrology Dialysis Transplantation. 36 (8): 1464–1473. doi:10.1093/ndt/gfaa135. ISSN 0931-0509. PMID 32810261.
  49. ^ Ariceta, Gema; Collard, Laure; Abroug, Saoussen; Moochhala, Shabbir H.; Gould, Edward; Boussetta, Abir; Ben Hmida, Mohamed; De, Sudarsana; Hunley, Tracy E.; Jarraya, Faical; Fraga, Gloria; Banos, Ana; Lindner, Elisabeth; Dehmel, Bastian; Schalk, Gesa (February 2023). "ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria". Pediatric Nephrology. 38 (2): 403–415. doi:10.1007/s00467-022-05591-5. ISSN 0931-041X. PMC 9763141. PMID 35552824.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxalobacter_formigenes&oldid=1256833770"